BrainAurora Medical Technology, a cognitive impairment digital therapeutics developer, saw its shares soar 5.28% in the intraday session on its trading debut in Hong Kong on Wednesday. The strong performance came after the company raised HK$501.3 million in net proceeds from its initial public offering (IPO) on the Hong Kong bourse.
The IPO was well-received by investors, with the public offering tranche being oversubscribed by 11.39 times. BrainAurora offered 181,112,000 shares at HK$3.22 apiece, with the international or placing shares being 1.01 times subscribed. The company issued 163 million shares through the placing tranche.
The successful IPO and strong stock performance on the debut day reflect investors' confidence in BrainAurora's potential in the digital therapeutics market, particularly in addressing cognitive impairment through its innovative solutions.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。